Open AccessUtility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?
Author(s) -
Unnati Desai,
Jyotsna M Joshi
Publication year - 2018
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_141_18
Subject(s) - medicine , para aminosalicylic acid , regimen , tuberculosis , observational study , adverse effect , aminosalicylic acid , drug , extensively drug resistant tuberculosis , pulmonary tuberculosis , pediatrics , surgery , antibiotics , streptomycin , pharmacology , mycobacterium tuberculosis , pathology , microbiology and biotechnology , biology
The World Health Organization drug-resistant tuberculosis (DR-TB) 2016 guidelines reclassified para-aminosalicylic acid (PAS) as Group D3 "add-on" drug. We studied our DR-TB data wherein PAS was widely and preferably used as a substitute in the standardized regimen in varied situations and report its utility in DR-TB.